CPT Code for PSA Testing in Medicare Patients with Prostate Cancer (Non-Screening)
For Medicare patients undergoing PSA testing for prostate cancer evaluation (not screening), use CPT code 84153 (PSA, total) with diagnosis codes indicating the specific clinical indication—such as personal history of prostate cancer (Z85.46), elevated PSA (R97.20), or active prostate cancer (C61)—rather than the screening-specific G0103 code.
Key Distinction: Diagnostic vs. Screening
The critical difference lies in the clinical context:
- G0103: Reserved exclusively for Medicare screening PSA in asymptomatic men without prostate cancer history, covered annually for men 50+ years
- 84153: Used for diagnostic/monitoring purposes when there is a clinical indication beyond routine screening
When to Use 84153 (Diagnostic PSA)
Use this code when PSA testing is performed for:
- Active prostate cancer monitoring during or after treatment
- Biochemical recurrence surveillance following definitive therapy
- Elevated PSA follow-up requiring further evaluation
- Symptomatic evaluation (lower urinary tract symptoms, abnormal DRE)
- Post-treatment monitoring (after prostatectomy, radiation, or other interventions)
- Patients with known prostate cancer at any stage
Critical Coding Requirements
The diagnosis code determines coverage and reimbursement. You must link 84153 to an appropriate ICD-10 code that reflects the non-screening indication:
- Z85.46: Personal history of malignant neoplasm of prostate
- C61: Malignant neoplasm of prostate (active disease)
- R97.20: Elevated PSA
- N40.x: Benign prostatic hyperplasia with symptoms
- R33.x: Retention of urine
Common Pitfall to Avoid
Never use G0103 for patients with a history of prostate cancer or those undergoing diagnostic evaluation. Medicare will deny claims if G0103 is billed with diagnosis codes indicating anything other than routine screening. The screening code is strictly for asymptomatic, average-risk screening scenarios.
Documentation Requirements
Ensure medical record documentation clearly indicates:
- Clinical indication for the PSA test (not routine screening)
- Relevant history (prior cancer, treatment, symptoms)
- Medical necessity for the test at this time
- Treatment plan based on results
Frequency Considerations
Unlike the annual limitation on G0103, diagnostic PSA testing (84153) has no predetermined frequency restrictions when medically necessary. The testing interval should be based on:
- Clinical guidelines for the specific indication
- Disease stage and risk stratification
- Treatment modality and timeline
- Individual patient factors and response to therapy
For post-treatment monitoring, PSA testing frequency typically follows established protocols (e.g., every 3-6 months initially after radical prostatectomy, then extending intervals based on undetectable PSA levels), which are covered under diagnostic coding when properly documented.